Toxicology – Glucagon

Core Concept

Glucagon is an endogenous peptide hormone best known for increasing blood glucose, but it also has positive chronotropic and inotropic cardiac effects.

In toxicology, its traditional major role is as an adjunct in beta-blocker poisoning.

Its role in calcium channel blocker (CCB) poisoning is much less established, and modern management of severe CCB toxicity relies more heavily on calcium, high-dose insulin euglycemia therapy, vasopressors, and other supportive measures.

Normal Physiologic Role

Glucagon is produced by pancreatic alpha cells, particularly in response to falling blood glucose.

Its metabolic effects include:

• Hepatic glycogenolysis
• Hepatic gluconeogenesis
• Increased blood glucose

Its ability to raise glucose depends partly on available hepatic glycogen stores.

Cardiac Mechanism

Glucagon binds to its own G-protein-coupled receptor rather than the beta-adrenergic receptor.

This activates adenylate cyclase:

Glucagon receptor → adenylate cyclase → ↑ cAMP → ↑ intracellular calcium

Cardiac consequences can include:

• Increased heart rate
• Increased contractility
• Improved cardiac output

Why It Can Work in Beta-Blocker Poisoning

Beta blockers inhibit beta-adrenergic receptor signaling.

Normally:

β-receptor stimulation → ↑ cAMP → increased cardiac activity

Glucagon can increase cAMP through a different receptor pathway.

Therefore:

β receptor blocked + glucagon receptor stimulated → cAMP can still increase

This is why glucagon has historically been described as bypassing beta-receptor blockade.

Beta-Blocker Poisoning

Severe beta-blocker toxicity may cause:

• Bradycardia
• Hypotension
• AV conduction abnormalities
• Cardiogenic shock
• Reduced myocardial contractility

Some agents have additional toxic properties.

For example:

• Propranolol can cause sodium-channel blockade and seizures.
• Sotalol can markedly prolong QT and cause torsades de pointes.

These additional mechanisms require their own targeted management.

Role of Glucagon in Beta-Blocker Toxicity

Glucagon can be considered for clinically important beta-blocker-associated:

• Bradycardia
• Hypotension
• Reduced myocardial contractility

A meaningful improvement in heart rate or blood pressure may support continuation of therapy.

However:

Glucagon should not be regarded as the sole or universally effective antidote for severe beta-blocker poisoning.

Evidence supporting its use is limited compared with the strength of its traditional reputation.

Modern Severe Beta-Blocker Management

Treatment is usually multimodal and may include:

• Airway and ventilatory support
• IV fluids when appropriate
• Atropine as an initial temporizing intervention
• Vasopressors
• Glucagon
• High-dose insulin euglycemia therapy (HIE)
• Correction of electrolyte and acid-base abnormalities
• Sodium bicarbonate for significant sodium-channel blockade
• Magnesium/electrical therapy for appropriate ventricular dysrhythmias
• Extracorporeal life support in selected refractory shock

Treatment should be based on the specific beta blocker and hemodynamic phenotype.

High-Dose Insulin Euglycemia Therapy

HIE has become particularly important for severe cardiogenic shock caused by beta blockers and especially calcium channel blockers.

Insulin can improve myocardial carbohydrate utilization and contractility.

Therapy requires close monitoring of:

• Blood glucose
• Potassium
• Hemodynamics
• Fluid balance

Glucagon and HIE are not mutually exclusive; they may be components of the same resuscitation strategy.

Calcium Channel Blocker Poisoning

Older sources frequently recommended glucagon for severe CCB poisoning.

Modern evidence for meaningful benefit is limited.

Severe CCB toxicity more commonly requires:

• IV calcium
• HIE
• Vasopressors
• Airway/ventilatory support
• Careful fluid management
• Selected rescue therapies for refractory cardiovascular collapse

Thus:

Glucagon is not a primary modern antidote for CCB poisoning.

CCB Toxicity and Hyperglycemia

CCBs, particularly severe poisoning with agents such as verapamil or diltiazem, can impair pancreatic insulin release.

This can produce:

• Hyperglycemia
• Insulin deficiency/resistance
• Reduced myocardial carbohydrate utilization

Marked hyperglycemia can therefore be a useful clue to severe CCB toxicity.

This metabolic disturbance is one reason HIE is important.

Hypoglycemia

Glucagon is also used outside toxicology to treat severe hypoglycemia when rapid oral carbohydrate or IV dextrose is not immediately feasible.

It increases glucose primarily by mobilizing hepatic glycogen.

However, its effectiveness may be reduced when glycogen stores are depleted.

Examples include:

• Prolonged fasting
• Severe malnutrition
• Chronic heavy alcohol use
• Advanced liver disease

When reliable IV access exists, dextrose provides a more direct glucose source.

Insulin and Sulfonylurea Poisoning

Glucagon is not the preferred definitive therapy for severe hypoglycemia from insulin or insulin secretagogues.

Insulin toxicity

Management centers on:

• Dextrose
• Frequent glucose monitoring
• Electrolyte monitoring
• Prolonged glucose support when necessary

Sulfonylurea toxicity

Dextrose corrects hypoglycemia, but glucose administration can stimulate further insulin release.

Octreotide is therefore important for recurrent sulfonylurea-induced hypoglycemia.

Glucagon can also stimulate insulin release, making it poorly suited as definitive treatment for sulfonylurea poisoning.

Nausea and Vomiting

A major practical limitation of glucagon is:

Nausea and vomiting are common, particularly when larger amounts are used.

This is especially concerning in poisoned patients with:

• Depressed consciousness
• Poor airway protection
• High aspiration risk

Airway status must therefore be considered carefully.

Hyperglycemia

Glucagon stimulates hepatic glucose release and can cause transient hyperglycemia.

Blood glucose should be monitored, especially when glucagon is being combined with other metabolic therapies.

Hypokalemia

Glucagon-associated metabolic changes can contribute to reductions in serum potassium.

In severe cardiotoxic poisoning, potassium abnormalities are especially important because they can influence:

• Cardiac conduction
• Dysrhythmia risk
• Response to HIE

Serial electrolyte monitoring is appropriate.

Pheochromocytoma

Glucagon can provoke catecholamine release in patients with pheochromocytoma.

This can produce severe:

• Hypertension
• Tachycardia
• Cardiovascular instability

Known pheochromocytoma is therefore an important precaution/contraindication.

Insulinoma

In a patient with an insulinoma, glucagon-induced hyperglycemia can provoke additional insulin secretion.

This may subsequently cause paradoxical or recurrent hypoglycemia.

Hypersensitivity

Serious allergic reactions are uncommon but possible.

Reported reactions include:

• Rash
• Hypersensitivity
• Rare anaphylaxis

Standard emergency treatment is required if a serious reaction occurs.

Warfarin Interaction

Older reports describe enhanced anticoagulant effects when glucagon is used with warfarin.

This is not usually the central concern during emergency toxicologic resuscitation, but coagulation status may be relevant in patients receiving chronic anticoagulation.

Preparation Issues

Severe beta-blocker poisoning historically required amounts of glucagon far greater than those contained in ordinary outpatient hypoglycemia rescue kits.

This can create practical problems with:

• Hospital supply
• Preparation
• Reconstitution
• Administration volume

Pharmacy involvement should occur early if substantial glucagon therapy is being considered.

Modern commercial formulations and diluents vary, so older warnings about a specific phenol-containing diluent should not be generalized to every current glucagon product.

Resource Limitation

One practical reason glucagon cannot be relied upon as the sole treatment of massive beta-blocker poisoning is that hospitals may not have large quantities immediately available.

Resuscitation should therefore proceed simultaneously with other appropriate therapies rather than waiting for glucagon procurement.

Assessing Response

Glucagon treatment should be assessed clinically by changes in:

• Heart rate
• Blood pressure
• Perfusion
• Mental status
• Cardiac output when available

A biochemical effect or transient increase in heart rate without improved perfusion is not necessarily an adequate therapeutic response.

Refractory Shock

If severe beta-blocker or CCB poisoning remains unstable despite initial treatment, escalation may involve:

• Vasopressor optimization
• HIE
• Mechanism-specific treatment
• Bedside echocardiography/hemodynamic assessment
• Toxicology consultation
• Mechanical circulatory support in selected cases

VA-ECMO may be considered in selected patients with otherwise refractory but potentially reversible cardiogenic shock.

Pregnancy

The historical FDA Category B designation is obsolete.

When glucagon is clinically indicated during pregnancy, treatment should be based on maternal condition and expected benefit.

In severe poisoning, restoring maternal circulation and perfusion is the immediate priority.

Monitoring in Cardiotoxic Poisoning

Monitor:

• Continuous ECG
• Heart rate
• Blood pressure
• Perfusion
• Mental status
• Blood glucose
• Potassium and other electrolytes
• Acid-base status
• Renal function
• Fluid balance

Bedside echocardiography can help distinguish predominant myocardial depression from vasodilatory shock and guide therapy.

Important Modernization of the Older Source

• Glucagon increases intracellular cAMP through its own receptor, bypassing beta-adrenergic receptor blockade.
• Its principal toxicologic role is as an adjunct in beta-blocker poisoning.
• The evidence supporting glucagon in beta-blocker poisoning is more limited than older textbooks sometimes imply.
• It should not delay vasopressors, HIE, or other appropriate therapies in severe shock.
• Glucagon has a much less established role in CCB poisoning and is not a primary modern antidote for it.
• HIE has become central to management of severe CCB cardiotoxicity and is also useful in selected severe beta-blocker poisoning.
• Propranolol-associated sodium-channel blockade requires mechanism-specific treatment rather than glucagon alone.
• Sotalol-associated QT prolongation/torsades requires appropriate dysrhythmia management.
• Glucagon is not preferred definitive therapy for insulin or sulfonylurea poisoning.
• Octreotide is particularly important for recurrent sulfonylurea-associated hypoglycemia.
• Nausea and vomiting are common with glucagon and may create aspiration risk.
• Known pheochromocytoma is an important concern because glucagon can provoke catecholamine release.
• Hospital glucagon supply can become a limiting factor in severe poisoning.
• Formulations and diluents have changed; historical phenol-diluent instructions should not automatically be applied to modern products.
• Historical pregnancy letter categories are obsolete.
• Exact high-dose toxicologic regimens should follow current poison-center or medical-toxicology protocols.

Key Points

• Glucagon activates its own receptor → increases cAMP → increases cardiac contractility and heart rate.
• Because this pathway does not require beta-receptor activation, glucagon can partially bypass beta-blockade.
• Its major toxicologic role is an adjunct for severe beta-blocker poisoning.
• Glucagon is not reliably effective enough to be the only treatment for severe beta-blocker shock.
• HIE and vasopressors are major components of modern treatment for severe cardiotoxic poisoning.
• Glucagon has only a limited role in modern CCB poisoning.
• Propranolol and sotalol have additional toxic mechanisms requiring specific treatment.
• Glucagon also raises blood glucose through hepatic glycogenolysis and gluconeogenesis.
• It may be ineffective for hypoglycemia when hepatic glycogen stores are severely depleted.
• Nausea and vomiting are common and can increase aspiration risk.
• Monitor glucose, potassium, ECG, blood pressure, and tissue perfusion.
• Refractory cardiogenic shock may require advanced mechanical circulatory support in selected patients.